Cite
HARVARD Citation
Johnson, T. et al. (2022). Real-World Comparison of Bezlotoxumab to Standard of Care Therapy for Prevention of Recurrent Clostridioides difficile Infection in Patients at High Risk for Recurrence. Clinical infectious diseases. pp. 1572-1578. [Online].